

## Effects of Anti-Tuberculous Drugs on Liver Function Profile in Libyan Patients with Tuberculosis

Mokhtar Hadida<sup>1</sup>, Amal Abo-Smhadana<sup>2</sup>, and Marwan Draid<sup>3\*</sup>

<sup>1</sup>Department of Family & Community Medicine, Faculty of Medicine, Tripoli University, 13662 Tripoli – Libya; <sup>2</sup>Division of Zoology, Department of Biological Sciences, School of Basic Sciences, Academy of Graduate Studies, 72331, Janzour, Libya, and <sup>3</sup>Department of Pharmacology, Toxicology & Forensic Medicine, Faculty of Veterinary Medicine, Tripoli University, 13662 Tripoli, Libya.

\*Correspondence to: Mokhtar M Hadida, PhD, Mtropead. DTCH,  
Department of Family and Community Health, Faculty of Medicine, Tripoli University, Tripoli, Libya  
email: elmokhtar53@yahoo.co.uk  
Tel: +218 913735613, Fax: +218 21 7217005

### ABSTRACT

The present prospective study was designed to conduct a local survey on patients under anti-tuberculosis therapy hospitalized in Abo-Seta hospital, Tripoli, Libya from the safety point of view. The study was carried out on 75 inpatients. The effects of the used drugs on some hematological parameters and liver function biomarkers were monitored for six-month period of treatment. Our survey showed that tuberculosis affects people with low and medium levels of education and with no job. The frequency of adverse effects related to treatment with Abo-Seta hospital regimen were decreases in WBCs count (-38.7%), RBCs count (-32.1%), platelets count (-33%) and hemoglobin concentration (-35.5%). However, in most of the cases, it was not necessary to modify the treatment regimen because of such side effects. Some parameters showed spontaneous recovery as RBCs count (+22.1%) and hemoglobin level (+20.1%). Combined therapy of ethambutol, isoniazid, pyrazinamide, and rifampicin has been used in Abo-Seta hospital, as a regimen for tuberculosis infection, may be associated with a high risk of hepatic toxicity during first month of treatment. However, during the remaining five months there was a good recovery of liver enzymes profile. Upon the data obtained from the present study, it could be concluded that TB patient after 6 month of treatment didn't develop multi-drug resistant tuberculosis (MDR-TB)

**Key words:** Tuberculosis, anti-tuberculosis therapy, safety profile.

### INTRODUCTION

Tuberculosis (TB) is one of the most common infectious diseases caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) (1). Tuberculosis is still a major cause of death from an infectious agent in developing countries, and constitutes a serious threat in large cities of industrialized countries (2). Environmental characteristics such as crowding and social factors had a large impact on exposure to the disease (3). In 1990, approximately, 1.7 billion humans were estimated to be infected worldwide (about one-third of the world's population) (4). Tuberculosis has reemerged as an important public health problem in past as well at recent time in Libya. At 2008 about 1000 TB cases had been reported (5). Also, in Libya, there were a few studies on such serious problem; one of these studies shows the number of

Libyan patients whom tuberculosis has been bacteriological confirmed (6), table 1.

**Table (1): Numbers of Libyan confirmed TB cases during 1990-2009 (6).**

Year	1990	1996	1999	2003	2005	2009
Incidence of TB / 100.000	41	40	23	20	18	16

*M. tuberculosis* was first isolated in 1882 by the German physician Robert Koch who received the Nobel Prize for this discovery. TB spreads most commonly by airborne transmission and can affect any part of the body but most often the lungs (5). TB, which occurs scattered throughout the body, is referred to as miliary TB. Extra-pulmonary TB is more common in immunodeficiency persons and in young

children (7). The classic symptoms of TB are a chronic cough with blood-tinged sputum, fever, night sweats, and weight loss. Infection of other organs causes a wide range of symptoms. Only 5% of people who are infected but not sick have latent TB infection. Those who have a latent infection are asymptomatic and do not feel sick. The diagnosis relies on radiology (chest X-Ray), tuberculin skin test, blood tests, as well as microscopic examination and microbiological culture of body fluids (8).

If not treated TB properly, it can be fatal (9). Today, persons with pulmonary TB can be cured with different types of regimens of antibiotics. One of these regimens followed by the Libyan National Center for Disease Control (NCDC), which is proposed by WHO as direct observed therapy for short period (DOTS). The protocol of this regimen is a 6-month course of antibiotics that includes isoniazid, rifampin, pyrazinamide, and ethambutol during the first 2 months. For our knowledge a combination of drugs may develop side effects on the body organs and the most related organ is liver, which is the metabolizing organ for all the received drugs. These side effects may differ from a patient to another due to the behavioral and cultural factors. Moreover, extensively drug-resistant tuberculosis is an emerging health problem that threatens TB control worldwide, since a perfect treatment for this disease has not yet been found.

In Libya, there is a huge gap between researches on anti-tuberculosis drugs and their effects on body functions during treatment period. Therefore, we designed this study to conduct a local survey on patients under anti-tuberculosis therapy hospitalized in Abo-Seta hospital, Tripoli, Libya from the safety point of view. The effects of the used drugs on the hematological parameters and liver function biomarkers are monitored for six-month period of treatment.

## **SUBJECTS AND METHODS**

### **Subjects:**

Seventy-five patients were inpatients, in 2009, in Abo-Seta hospital, in the west north of Libya, diagnosed as newly

infected by TB. All patients were diagnosed as pulmonary tuberculosis by chest X-Ray, medical history and sputum analysis. Some patients had normal liver function while others had abnormal due to positive hepatitis. Prior-therapy samples were taken as controls.

### **Clinical monitoring:**

Complete history background was taken from all patients via questionnaires involving name, sex, nationality, occupation, social status, smoking, residence, education, number of family members, number of rooms, previous treatment, first symptoms, fever, sweating, chest pain, weakness, anorexia, weight, other diseases and any other information, if any. Directly observed treatment (DOT) were also recorded according to CDC (2000) (8).

### **Methods of treatment:**

Patients received the following therapeutic regimen: isoniazid 50 mg once a day, rifampicin 10 mg once a day, pyrazinamide 25 mg once a day, ethambutol 15 mg once a day and/or streptomycin 0.75 g once a day. All patients were treated for 6 months.

### **Laboratory monitoring:**

#### **1. Monitoring of hematological parameters:**

Complete blood count (CBC) with more emphases regarding the effects on red blood cells (RBCs) count, white blood cells (WBCs) count were been determined using an automated hematology Sysmex (KS-21N; Sysmex corporation, (Kobe, Japan)), in Libyan National Center for Infectious Disease Prevention and Control (NCDC). Anti-HIV, anti-HBV, anti-HCV antibodies were detected by ELISA. For CBC, blood samples of 5 ml were collected in special heparinized tubes to prevent clotting of the samples; additional 10 ml were collected without anticoagulant for detection for HIV, HBV and HBV antibodies.

#### **2. Monitoring of the drug effect on liver functional parameters:**

Patients' liver functions; alanine amino-transferase (ALT) and aspartate amino-transferase (AST) were determined by automatic biochemical analytic apparatus using a spectrophotometer (APPLIED

BIOSYSTEMS BTS 310, Biosystems of New England, Inc. (Waltham, Massachusetts, USA)) at the Libyan National Center for Infectious Disease Prevention and Control, when the patients had empty stomachs. Liver function of the patients was examined repeatedly every 4 weeks till 6 months after therapy. Test tubes without anti-coagulant agent used and filled every time with 10 ml of blood.

### 3. Monitoring hepatic adaptation:

It was detected by automatic biochemical analytic apparatus using a spectrophotometer APPLIED BIOSYSTEMS BTS 310, Biosystems of New England, Inc. (Waltham, Massachusetts, USA)) at the Libyan National Center for Infectious Disease Prevention and Control. The same previous test tube sample was used for this detection.

### Statistical Analysis:

Data was analyzed by using statistics package for social sciences (SPSS Statistics 17.0.1) computer software package for statistical analysis (IBM Corporation, IBM Software Group's Business Analytics Portfolio (USA). Results were expressed as mean  $\pm$  standard deviation (SD). Statistical test used was student's unpaired *t*-test, P value  $< 0.05$  was considered statistically significant.

## RESULTS

### 1. Clinical monitoring: Characteristics of different patients (questionnaire analysis):

Considering the seventy five TB inpatients, analysis of the questionnaire replies (**table 2**) revealed that age group 30-39 years is more affected by tuberculosis more than other age groups; single patients are more affected by tuberculosis more than

married patients (70.7% vs. 29.3%); the smokers are more susceptible to TB infection than non-smokers (69.3% vs. 30.7%); highly educated patients are less affected (2.6%) when compared to medium- and low-leveled educated ones (78.6%). Jobless people were with higher exposure to pulmonary tuberculosis (58.6%) than employees (41.4%). Within the examined group of patients, many patients were infected with other disease conditions as HIV (32%), HBV (3%), and HCV (27%).

Six months after anti-TB therapy, all the inpatients suffered from different symptoms, including fatigue, decreased appetite, dizziness, nausea ... etc.

### 2. Laboratory monitoring:

#### 2.1. Determination of hematological parameters:

As shown in table (3), the anti-tuberculosis therapy caused a gradual significant decrease in the number of WBCs count from the beginning of treatment until the end of course (control samples =  $9.32 \pm 0.88 \times 10^3$ , after one month =  $7.69 \pm 0.35 \times 10^3$ , and after six months =  $5.71 \pm 0.55 \times 10^3$ ,  $n = 75$ ;  $P < 0.05$ ), with percentage range of -17.5% to -38.7%, respectively.

Also, RBCs count showed a significant decrease after one month of treatment ( $5.89 \pm 0.36 \times 10^6$  in control samples vs.  $3.66 \pm 0.48 \times 10^6$  after one month,  $P < 0.05$ ), with percentage of -32.1%. However, by the end of the course, there was a significant recovery in number of RBCs in the end of the course compared after one of treatment ( $4.70 \pm 0.35 \times 10^6$ , when compared with the value  $3.66 \pm 0.48 \times 10^6$  that was recorded after one months;  $n = 75$ ;  $P < 0.05$ ) with a recovery percentage of +22.1%.

**Table (2):** The sociodemographic and clinical characteristics among 75 TB infection inpatients.

Variables	TB patients (n=75)	
	No.	%
<b>Age group (years):</b>		
<b>11-19</b>	3	4.0
<b>20-29</b>	11	14.7
<b>30-39</b>	38	50.7
<b>40-49</b>	17	22.6
<b>50-59</b>	5	6.6
<b>≥ 60</b>	1	1.4
<b>Marital status:</b>		
<b>Single</b>	53	70.7
<b>Married</b>	22	29.3
<b>Educational level:</b>		
<b>High</b>	16	21.4
<b>Medium/low</b>	59	78.6
<b>Job:</b>		
<b>Have no job</b>	44	58.6
<b>Have a job</b>	31	41.4
<b>Smoking status:</b>		
<b>Yes</b>	52	69.3
<b>No</b>	23	30.7
<b>Associated infections:</b>		
<b>HIV</b>	24	32
<b>HBV</b>	2	2.7
<b>HCV</b>	20	26.7

Platelets count exhibited a significant decrease from the beginning of treatment until the end of course (in control samples =  $429.6 \pm 11.9 \times 10^3$ , after one month =  $330.61 \pm 32.69 \times 10^3$ , after six months =  $277.27 \pm 15.39 \times 10^3$ ;  $n = 75$ ;  $P < 0.05$ ) with percentages of -23% and -33%, respectively.

Hemoglobin level exhibited a significant decrease after one month of treatment ( $14.52 \pm 0.45$  g/dl in control samples vs.  $9.74 \pm 1.22$  g/dl after one month;  $n=75$ ;  $P < 0.05$ ) with percentage of -35.5%. However within the course of treatment there was a spontaneous recovery in hemoglobin level that was significant after 6 months of treatment ( $12.19 \pm 0.15$ g/dl compared to  $9.74 \pm 1.22$  g/dl that was recorded after one month;  $n = 75$ ;  $P < 0.05$ ) and this increase was with a percentage of +20.1%.

## 2.2. Effect of anti-tuberculous drugs on liver function:

As shown in table (4), ALT level was increased after one month of treatment ( $36.25 \pm 1.39$  U/L in control samples vs.  $64.6 \pm 3.55$  U/L after one month of therapy;  $n = 75$ ;  $P < 0.05$ ) with an increase percentage of +43.9%. However, there was a significant gradual recovery towards the normal value starting from the 2<sup>nd</sup> month until the end of course ( $39.28 \pm 1.33$  U/L after six months, compared to  $64.6 \pm 3.55$  U/L, the value that was recorded after one month;  $n = 75$ ;  $P < 0.05$ ) with a recovery percentage of -39.2%.

**Table 3:** Show the effect of antituberculosis treatment during 6 month on WBC, RBC, platelets and hemoglobin.

Parameter	Before treatment Mean ± SD	Antituberculosis treatment duration (Month)					
		1st Mean ± SD	2nd Mean ± SD	3rd Mean ± SD	4th Mean ± SD	5th Mean ± SD	6th Mean ± SD
WBC (x10 <sup>3</sup> )	9.32 ± 0.88	7.69 ± 0.35*	8.25 ± 1.01	7.52 ± 0.60	7.13 ± 0.70	6.30 ± 0.63	5.71 ± 0.55#
RBC (x10 <sup>6</sup> )	5.89 ± 0.36	3.66 ± 0.48*	4.04 ± 0.18	4.29 ± 0.21	4.34 ± 0.16	4.54 ± 0.25	4.70 ± 0.35#
platelets (x10 <sup>3</sup> )	429.60 ± 11.90	330.61 ± 32.69*	317.01 ± 60.75	300.00 ± 38.73	277.75 ± 15.29	283.37 ± 12.65	277.27 ± 15.39#
Hemoglobin (g/dl)	14.52 ± 0.45	9.74 ± 1.22*	10.67 ± 1.01	11.04 ± 1.02	11.41 ± 1.06	12.04 ± 1.03	12.19 ± 0.15#

-Values are means ±SD, n=75, P < 0.05

-\* Mean value was significantly different to that at control (P < 0.05).

-# Mean value was significantly different to that at First month (P < 0.05)

### 2.3. Hepatic adaptation:

As shown in table (4), AST had been increased after one month of treatment (30.31 ± 1.53 U/L in control samples vs. 47.57 ± 2.98 U/L after one month of anti-TB therapy; n = 75, P < 0.05) with an increase percentage of +36.3%. However, parallel to ALT, there was a significant gradual recovery expressed as gradual decrease starting from the 2<sup>nd</sup> month until the end of course (35.03 ± 0.55 U/L after six month, compared to 47.57 ± 2.98 U/L, the value that was recorded after one month; n = 75, P < 0.05) with a percentage recovery of -25.8%.

Similarly, ALP showed an initial increase after one month of treatment (156.17 ± 21.35 U/L in control samples vs. 281.83 ± 45.8 U/L after one month of anti-TB therapy, n = 75, P < 0.05) with a percentage of +44.6%. That result was followed by a gradual recovery starting from the second month till the end of the course at 6 months (256.67 ± 34.93 U/L after six month, compared to 281.83 ± 45.8 U/L, the value that was recorded after one month of therapy; n = 75; P < 0.05) with a recovery percentage of -8.9%.

**Table 4:** Show the effect of antituberculosis with in 6 month on liver function enzyme.

Parameter	Before treatment Mean ± SD	Antituberculosis treatment duration (Month)					
		1st	2nd	3rd	4th	5th	6th
		Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD
ALT (U/L)	36.25 ± 1.39	64.60 ± 3.55*	58.68 ± 2.66	51.00 ± 1.39	47.55 ± 1.27	42.63 ± 1.63	39.28 ± 1.33#
AST (U/L)	30.31 ± 1.53	47.57 ± 2.98*	39.87 ± 1.87	38.82 ± 0.90	36.67 ± 1.01	36.30 ± 0.74	35.03 ± 0.55#
Alkaline phosphatase (U/L)	156.17 ± 21.35	281.83 ± 45.80*	270.28 ± 30.69	257.78 ± 53.65	248.00 ± 45.94	239.00 ± 39.85	256.67 ± 34.93

- Values are means  $\pm$ SD, n=75, P < 0.05

-\* Mean value was significantly different to that at control (P < 0.05)

-# Mean value was significantly different to that at First month (P < 0.05)

## DISCUSSION

The wide prevalence of tuberculosis throughout the world makes it social and economical burden especially for developing countries and the use of anti-tuberculous drugs is an optimistic approach for this problem. However certain reservations associated with its use need to be properly evaluated especially anti-tuberculosis treatment-induced liver injury and the predisposing factors that add to this hepatotoxicity (10).

Our survey shows that tuberculosis in Libya can be related to people with low income, bad habits and low educational level, however, some communities provide a better environment for disease

transmission than others. Previous surveys have documented great disparities in rates of tuberculosis among neighborhoods (11). These differences depended, in part, on community-level, ecological risk factors that facilitate transmission-poverty, crowding, and other markers of deprivation have long been associated with increased rates of tuberculosis (12, 13). In addition to ensuring treatment efficiency, countries health departments collect case-specific demographic information (e.g., age, race, foreign-born status) and disease information (e.g., site of infection, drug resistance) (14). Some other studies have supported our finding and the role of ecological risk

factors, such as low income, lack of social capital, and overcrowding, in tuberculosis disease (15, 11, 16, 17). Although genetic differences have been linked to increased mycobacterial susceptibility (18, 19), our study has considered the nationality of the patients under investigation whether they are Libyans or non-Libyans; we found that most of the patients (94.7%) were Libyans; and this may be explained on the basis of most of non-Libyan patients are not recorded, and all foreigners may go to other centers because of cost concern or may leave the country. Our results was explained within the context of recent research on “social capital” as a major factor for tuberculosis in Tripoli area as shown that 70.7% of patients were single, for our knowledge always single people cannot manage their food or habit culture.

Major infectious cause of mortality in India and many other developing countries include lower respiratory tract infections, HIV/AIDS, perinatal conditions, diarrhoeal diseases, tuberculosis, and malaria (20); and all these kinds of infectious diseases are related to the low level of education and poverty. This statement agrees with our study, where, 78.6% of monitored patients were found to have low or medium degree of education and 58.6% were jobless and both of these concerns were strongly related to poverty.

Smoking and tobacco uses are usually related in young individuals to infections such as lower respiratory tract infections and tuberculosis and in middle aged and the elderly to cardiovascular diseases, cancer, and chronic lung diseases (21, 20, 22). It is well known in the developed countries that smoking use is most prevalent among the least privileged groups (23, 24). These groups are the unhealthiest and face the largest health inequities in terms of preventive, curative and rehabilitative therapies (25). As shown in our survey, we have found that most of our TB patients are smokers (69.3%); this finding is consistent with other reports; for example, tobacco smoking was associated with a two-fold increased risk of active tuberculosis in a representative cohort of Taiwan's population (26).

Leukopenia may occur in the course of treatment with anti-tuberculosis drugs,

but it is not necessary to stop the chemotherapy immediately because of this fact, as the WBCs count recovers spontaneously or remains under stable leukopenic state during the course of chemotherapy in most cases. However, when leukopenia appears, the peripheral blood counts must be checked cautiously, and the chemotherapy should be stopped if the WBCs count progressively decreases. The patients who showed leucopenia due to anti-tuberculosis drugs may have had weaker natural and acquired cell-mediated immunologic response to tuberculosis infection, and more vulnerable bone marrow cells and hepatic cells to anti-tuberculosis drugs than the control. Our result showed leucopenia about -39.83% starting from the beginning of treatment figure. This finding is in agreement with Nagayama *et al.* (2004) (27), who recorded leucopenia due to anti-tuberculous chemotherapy, including rifampicin and isoniazid.

Since RBCs can behave as bioreactors that are able to convert pro drugs to membrane-releasable active drugs, new compounds (AZTpEMB, AZTpEMBpAZT, and AZTp2EMB) comprising both anti retro viral and anti microbial drugs were designed and synthesized. Among these, only AZTp2EMB was hydrolyzed by erythrocyte enzymes and could be encapsulated inside RBCs (28). Our data expressed that RBCs count decreased significantly (-32.1%) after one month of anti-TB treatment; however, from 2<sup>nd</sup> month, it started to recover. This may be explained on the basis of that initially RBCs undergo deformation to protect itself from drug toxicity.

On the other hand, some other studies indicated that none of the anti-tuberculosis drugs is without adverse reactions but only rarely are the adverse reactions lives threatening. Thrombocytopenia (TCP) is a well-known complication following the administration of certain drugs and is characterized by rapid lowering of the platelet count whenever the offending drug is taken by the sensitized individual. Rifampicin-induced TCP is a rarely reported adverse reaction (29).

To test development of thrombocytopenia in inpatients under anti-

TB therapy, platelet count was included in the study. Although there was a decrease in platelet count after treatment as compared to pre treatment, it was within the normal range. This decrease in platelet count may be due to Rifampicin whose one of the side effects is thrombocytopenia. The result of the present study was in agreement with the study of **Nagayama *et al.* (2004) (27)** that was carried out in Japan. Besides, another study by **Handin (1991) (30)** indicated that many drugs had effect on platelets in the form of reducing their number; however, upon discontinuation of the suspected drug, there will be regain of the platelets number. TCP was also recorded as an adverse reaction associated with intermittent rifampicin regimen by **Toman (1989) (31)**. During using anti-tuberculosis drugs, if purpura occurred, rifampicin should be stopped immediately and should not be given again even in small doses **(32)**. Those previous data are in agreement with these stated in the present study that taking anti-tuberculosis drugs had a significant decreasing effect on the platelets number at a percentage of -35.5%.

Three fourths of the monitored patients suffered from low hemoglobin level so that they may fall in the category of moderate to severe anemia. Nutritional status of our patients was very poor and 61 patients (91%) of them were below 18.5 kg/m<sup>2</sup> BMI; and 27% of the patients showed the hypoalbuminemia and this may be one of the risk factors of anti-TB therapy-induced hepatotoxicity **(33)**. A group of researchers concluded that improvement of hematological status was dependent only on the improvement of the disease process as **Das *et al.* (2003) (34)**. Although a few reports referred to the effect of anti-TB therapy on the hemoglobin level, yet, our study recorded clearly that the used drugs had a lowering effect on the hemoglobin level only in first month in treatment at a percentage of -33%.

The possible explanation of anti-TB therapy-induced hepatotoxicity in malnutrition is the depletion of glutathione stores that makes one vulnerable to oxidative injuries. Our study depicts the same result as a study conducted at India

showing three times higher incidence of anti-TB therapy-induced hepatotoxicity in malnourished patients **(35)**. For our knowledge a combination of drugs will develop side effects on the human body organs, and the most related organ is the liver. Anti-tuberculosis medication frequently causes disturbance to liver function tests and may cause serious liver function dysfunction **(36)**. Enzymes for drug metabolism in hepatocyte microcosms may have a congenital defect, malformation, low activity, or be inhibited by drugs, so drug metabolites are very toxic to hepatocytes. Another reason is the hypersensitivity to drugs. The drugs may act as haptens causing allergic reaction by immune mechanism leading to the single ALT increase in clinical situation. Commonly used anti-TB drugs, such as isoniazid, rifampicin, pyrazinamide, ethambutol, etc., are all hepatotoxic, especially when rifampicin and pyrazinamide are used in combination **(37)**. Isoniazid causes hepatic damage either by the toxicity of or hypersensitivity induced by its metabolite-acehydrazide. Rifampicin may accelerate the metabolism of isoniazid as a strong enzyme inducer resulting in the increase of acehydrazide. Acehydrazide combines with bio macromolecules in liver leading to hepatocellular damage usually seen in aged patients with excessive drinking, malnutrition or a liver ailment. Pyrazinamide's hepatotoxicity is dose-dependent and the general dose rarely causes hepatic damage. Isoniazid and rifampicin are the first line anti-TB medicines because of their strong bactericidal effects. However, rifabutin, amikacin, ofloxacin, levofloxacin, etc., treatment plan have not been reported with obvious hepatotoxicity **(38, 39)**. It had been reported that rifampin appears to enhance metabolic hepatocellular idiosyncratic reaction in patients receiving isoniazid, perhaps by promoting the formation of toxic isoniazid metabolites **(40)**. The use of multidrug regimens for the treatment of tuberculosis based on the combination of isoniazid, rifampin, ethambutol, and/or pyrazinamide has proven to be a highly effective therapy **(41)**. However, its



effectiveness is offset by the increased incidence of drug-induced hepatotoxicity. The development of drug-induced hepatotoxicity is often of great concern, as it often necessitates the cessation or modification of treatment (42). The occurrence of liver injury during anti-tuberculosis treatment varies, and appears to be much higher in developing countries (up to 39%) than in developed countries (3-4%) (43); despite of the use of similar regimens. The reasons for this higher incidence of drug-induced hepatotoxicity in developing countries remain unclear. It has been suggested that this may be attributable to viral hepatitis, which is particularly prevalent in the developing world (44).

In our study the patients developed anti-TB-induced hepatotoxicities indicated by increasing of all of the three enzymes, 43.9% for ALT, 36.6% for AST and 44.6% for ALK that almost overlap the study conducted in Japan by Ohno *et al.* (2000) (45).

The combination of multi drug therapy for tuberculosis has been associated with increased risk of hepatotoxicity when compared with INH mono therapy used for TB prophylaxis (46). The reported incidence of anti-TB-induced hepatotoxicity is different in various countries though not fully understood but could be due to the characteristics and the risk factors of the population studied, the different diagnostic criteria used to define hepatotoxicity, different geographical areas, tests carried out during follow ups and the type of monitoring (47). Parallel studies conducted in Nepal and Hong Kong resulted in increase in hepatic biomarkers with percentages of 8% and 13%, respectively. Four prospective Indian studies documented the risk of anti-TB-induced hepatotoxicity as 11.5% compared with 4.3% in fourteen published studies from west (48). Hepatotoxicity occurs generally within weeks to months rather than the days to weeks of onset seen with hypersensitivity reactions (49). In addition, only one study (50) has examined the risk of drug-induced hepatotoxicity in standard short-course anti-TB treatment in patients with clinical TB. Studies in the 1950s suggested that elevated glutamate pyruvate transaminases occurred in 20%, and overt hepatitis in 8%, of those

treated with pyrazinamide, which has some structural resemblance to isoniazid (1). Experience with lower dose regimens, in combination with other agents, suggests that there is only a small risk of hepatocellular injury (51), though cases of fatal hepatic necrosis have been described (52). Younossian *et al.* (2005) (53) concluded that combining pyrazinamide and ethambutol for latent tuberculosis infection may be associated with a high risk of hepatic toxicity, and warrants close monitoring. There is clearly a need for alternative preventive treatments for contacts exposed to multidrug-resistant tuberculosis. Thompson *et al.* (1995) (36) suggested a protocol for using liver function tests to monitor for liver damage, and give recommendations on what action to take when these become abnormal and same suggestion been supported by other group as Parthasarathy *et al.* (1986) (42). In a study in Hong Kong, 1,386 Chinese patients with sputum smear-positive pulmonary tuberculosis were under treatment for 6 month with combinations of anti-tuberculosis drugs recorded non-significant differences between the regimens with and without streptomycin (54). Even the recovery of the liver is a normal mechanism as the body rebuilds its own cells, which agree with our results for all three liver function enzymes. There are many risk factors of hepatic damage during the course of anti-TB treatment, such as the type of tuberculosis, recurrent tuberculosis, HBV infection, alcohol drinking, age, nutrition status, heredity, individual difference and immune status, etc. Scholars outside China reported that most of hepatocytes in HBV carriers without clinical symptoms had changes in histology and spot necrosis in some hepatocytes. One researcher took liver biopsies from 25 pulmonary tuberculosis patients with HBV infection during the course of anti-TB treatment and discovered that all the patients with liver dysfunction suffered from viral hepatitis, even liver cirrhosis. Hepatic damage of the patients with pulmonary tuberculosis during the course of anti-TB treatment was related to HBV infection and pre-existing pathologic changes in liver. Anti-TB medicines only aggravated pre-existing hepatic damage (55, 56). So, HBV infection or pre-existing liver

ailment might be an important risk factor (57, 58). Hepatotoxicity caused by anti-TB medicines was liable to happen in the first 2-3 months of aggressive anti-TB treatment. Hepatic damage of the patients with positive HBV was caused by viral damage overlapped by medicine damage (59). The prevalence of TB was reported to be higher among hepatitis-C virus-infected (HCV) patients than among those without infection (60). However, the relationship between HCV infection and the development of drug-induced hepatotoxicity during treatment for TB is not well defined in literature (50, 61). Percentage of patients which are infected with other kind of disease can be seen in HIV.

**In conclusion**, we can state that manifestations of side effects related to anti-tuberculosis treatment with our regimen in the population of the tuberculosis inpatient clinic of the Abo-Seta hospital are apparent. However, in the great majority of cases, it was not necessary to modify the treatment regimen due to adverse effects. These results show the importance of the early recognition of these effects and the early initiation of the appropriate approach. It is fundamental to follow the recommendation of the National Health Foundation Guide to Epidemiological Surveillance of Tuberculosis (62) that clinical follow-up evaluations of patients be carried out by health professionals at least once a month and includes an interview regarding the possible signs and symptoms related to side effects.

## REFERENCES

- (1) **BMRC (British Medical Research Council) (1952)**: The treatment of pulmonary tuberculosis with isoniazide. An interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. *Br. Med. J.*, ii: 735-746.
- (2) **Snider DE, Raviglione M, Kochi A (1994)**: Global burden of tuberculosis. In *Tuberculosis: Pathogenesis, Protection, and Control*, pp. 3-11. Edited by B. R. Bloom. Washington, DC: American Society for Microbiology.
- (3) **Rubel AJ, Garro LC (1992)**: Social and cultural factors in the successful control of tuberculosis. *Public Health Rep.*, **107**: 626-36.
- (4) **Raviglione MC, Snider D E, Jr Kochi A (1995)**: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA*, **273**: 220-226.
- (5) **WHO (World Health Organization) (2008)**. Tuberculosis Fact sheet No. 104 - Global and regional incidence. Geneva, Switzerland: World Health Organization.
- (6) **NCDC (National Center for Infectious Disease Prevention and Control) (2009)**: Tuberculosis prevalence rate. Local Report.
- (7) **Aranaz A, Liébana E, Gómez-Mampaso E, Galán JC, Cousins D, Ortega A, Blázquez J, Baquero F, Mateos A, Suárez G, Domínguez L (1999)**: Mycobacterium Tuberculosis subsp. caprae subsp. nov.: a taxonomic study of a new member of the Mycobacterium tuberculosis complex isolated from goats in Spain. *Int. J. Syst. Bacteriol.*, **49**:1263-1273.
- (8) **CDC (Centers for Disease Control and Prevention) (2000)**: Division of Tuberculosis Elimination. Core Curriculum on Tuberculosis: What the Clinician Should Know. 4th edition. Updated August 2003.
- (9) **Alteri CJ, Xicohténcatl-Cortes J, Hess S, Caballero-Olín G, Girón JA, Friedman RL (2007)**: Mycobacterium tuberculosis produces pili during human infection. *Proc. Natl. Acad. Sci. U S A.*, **104**: 5145-5150.
- (10) **Blajchman MA, Lowry RC, Petil JE, Stradling P (1970)**: Rifampicin induced immune thrombocytopenia. *Brit. Med. J.*, **3**: 24-26.
- (11) **Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Mendez A (2001)**: Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984-1992. *Am. J. Public Health*, **91**: 1487-1493.
- (12) **Hetherington HW, Landis M, Opie A (1929)**: Survey to determine the prevalence of tuberculosis infection in school children. *Am. Rev. Tuberc.*, 421.
- (13) **Puccini G (1896)**: La Boháeme. Milan, Italy: G Ricordi & C.
- (14) **Krieger N, Chen JT, Ebel G (1997)**: Can we monitor socioeconomic inequalities in health? A survey of U.S. health departments' data collection and reporting practices. *Public Health Rep.*, **112**: 481-491.
- (15) **Spence DP, Hotchkiss J, Williams CS, Davies PD (1993)**: Tuberculosis and poverty. *B.M.J.*, **307**: 759-761.
- (16) **Krieger N, Waterman PD, Chen JT, Soobader MJ, Subramanian SV (2003)**: Monitoring socioeconomic inequalities in sexually transmitted infections, tuberculosis, and violence: geocoding and choice of area-based

- socioeconomic measures-the public health disparities geocoding project (US). *Public Health Rep.*, **118**:240-260.
- (17) **Holtgrave DR, Crosby RA (2004)**: Social determinants of tuberculosis case rates in the United States. *Am. J. Prev. Med.*, **26**: 159-162.
- (18) **Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD, Skamene E, Lagrange PH, Schurr E (1998)**: Susceptibility to leprosy is linked to the human NRAMP1 gene. *J. Infect. Dis.*, **177**: 133-145.
- (19) **Ma X, Reich RA, Wright JA, Tooker HR, Teeter LD, Musser JM, Graviss EA (2003)**: Association between interleukin-8 gene alleles and human susceptibility to tuberculosis disease. *J. Infect. Dis.*, **188**: 349-355.
- (20) **WHO (World Health Organization) (2002)**: Reducing risks, promoting healthy life. World Health Report 2002. Geneva, Switzerland: World Health Organization.
- (21) **Jha P, Chaloupka F (2000)**: Tobacco control in developing countries. Oxford: Oxford University Press.
- (22) **Gajalakshmi V, Peto R, Kanaka TS, Jha P (2003)**: Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. *Lancet.*, **362**: 507-515.
- (23) **Mackenbach JP, Kunst AE, Groenohof F, Geurts JJ (1997)**: Socioeconomic inequalities in morbidity and mortality in western Europe. The EU Working Group on Socioeconomic Inequalities in Health. *Lancet*; **349**: 1655-1659.
- (24) **Leon DA, Walt G (2001)**: Poverty inequality and health: an international perspective. Oxford: Oxford University Press.
- (25) **Berkman L, Kawachi I (2000)**: Social epidemiology. New York: Oxford University Press.
- (26) **Lin HH, Ezzati M, Chang HY, Murray M (2009)**: Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. *Am. J. Respir. Crit. Care Med.*, **180**: 475-80.
- (27) **Nagayama N, Shishido Y, Masunda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Komatsu H, Yotsumoto H (2004)**: Leukopenia due to anti-tuberculous chemotherapy including rifampicin and Isoniazid. *Kekkaku*, **79**: 341-348.
- (28) **Rossi L, Brandi G, Schiavano GF, Scarfi S, Millo E, Damonte G, Benatti U, De Flora A, Magnani M (1999)**: Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. *AIDS Res. Hum. Retroviruses*, **15**:345-353.
- (29) **Ferguson GC (1971)**: Rifampicin and thrombocytopenia (Letter). *Brit. Med. J.*, **3**: 638.
- (30) **Handin RI (1991)**: Disorders of the platelet and vessel wall. In Harrison's Principles of Internal Med. Vol. 2. 12th Ed. Me Graw Hill, Inc., 1501.
- (31) **Toman K (1989)**: What is the toxicity of anti- tuberculosis drugs in Tuberculosis case finding and chemotherapy? Questions and Answers, 1st Edition, Jaypee Brothers, New Delhi, 101.
- (32) **Aquinas M, Allan WG, Horsfall PA, Jenkins PK, Hung-Yan W, Girling D, Tall R, Fox W (1971)**: Adverse reactions to daily and intermittent regimens for pulmonary tuberculosis in Hong Kong. *Brit. Med. J.*, **1**: 765-771.
- (33) **Shakya R, Rao BS, Shrestha B (2004)**: Evaluation of risk factors for antituberculosis drug induced hepatotoxicity in Nepalese population. *Ann. Pharmacother.*, **38**:1074-1079
- (34) **Das BS, Devi U, Mohan Rao C, Srivastava VK, Rath PK, Das BS (2003)**: Effect of iron supplementation on mild to moderate anaemia in pulmonary tuberculosis. *Br. J. Nutr.*, **90**:541-550.
- (35) **Mehta S (1990)**: Malnutrition and drugs: Clinical implications. *Dev. Pharmacol. Ther.*, **15**:159-165.
- (36) **Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N (1995)**: Anti-tuberculosis medication and the liver: dangers and recommendations in management. *Eur. Respir. J.*, **8**: 1384-1388.
- (37) **Yew WW, Chau CH, Wong PC, Lee J, Wong CF, Cheung SW, Chan CY, Cheng AF (1995)**: Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. *Drugs Exp. Clin. Res.*, **21**: 79-83.
- (38) **Yew WW, Lee J, Wong PC, Kwan SY (1992)**: Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. *Int. J. Clin. Pharmacol. Res.*, **12**: 173-178.
- (39) **Schaberg T, Rebhan K, Lode H (1996)**: Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. *Eur. Respir. J.*, **9**: 2026-2030.
- (40) **Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P (1986)**: Rifampin-induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. *Am. Rev. Respir. Dis.*, **133**: 1072-1075.
- (41) **Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR,**

- Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society (2003):** American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. *Am. J. Respir. Crit. Care Med.*, **167**: 603-662.
- (42) Parthasarathy R, Samara GR, Janardhanan B (1986):** Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. *Tubercule.*, **67**: 99-108.
- (43) BTS (British Thoracic Society) (1981):** A controlled trial of six months chemotherapy in pulmonary tuberculosis: first report; results during chemotherapy. *Br. J. Dis. Chest.*, **75**: 141-153.
- (44) Türktaş H, Unsal M, Tülek N, Oruç O (1994):** Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. *Tuber. Lung Dis.*, **75**: 58-60.
- (45) Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J (2000):** Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP-induced hepatotoxicity. *Intl. J. of Tuberc. Lung Dis.*, **4**: 256-261.
- (46) Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, et al. (1995):** Delirious influence of pyrazinamide on the outcome of patient with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. *Hepatology*, **21**: 929-932.
- (47) Villor AF, Sopena B, Villor JF (2004):** The influence of risk factors on the severity of antituberculosis drug induced hepatotoxicity. *Int. J. Tuberc. Lung disease*, **8**: 1499-1505.
- (48) Steele MA, Burk RF, DesPrez RM (1991):** Hepatitis with INH and RMP: a meta-analysis. *Chest*, **99**: 465-71.
- (49) Attri S, Rana SV, Vaiphie K, Katyal R, Sodhi CP, Kanwar S, Singh K (2001):** Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. *Indian J. Exp. Biol.*, **39**: 436-440.
- (50) Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE (1998):** Antituberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. *Am. J. Respir. Crit. Care Med.*, **157**: 1871-1876.
- (51) Hong Kong Chest Service/British Medical Research Council (1981):** Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. *Lancet.*, **i**: 171-174.
- (52) Danan G, Pessayre D, Larrey D, Benhammou JP (1981):** Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again. *Lancet.*, **2**: 1057-1058.
- (53) Younossian AB, Rochat T, Ketterer J-P, Wacker J, Janssens J-P (2005):** High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. *Eur. Respir. J.*, **26**: 462-464.
- (54) Hong Kong Chest Service/British Medical Research Council (1991):** Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. *Am. Rev. Respir. Dis.*, **143**: 700-706.
- (55) van den Brande P, van Steenberg W, Vervoort G, Demedts M (1995):** Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. *Am. J. Respir. Crit. Care Med.*, **152**: 1705-1708.
- (56) Qu YW, Guo Y, Zhao GD, He HZ, Liu Y (2001):** The mechanism and prevention of hepatic damage caused by anti-TB drug. *Zhongguo Fanglao Zazhi*, **23**: 56-57.
- (57) Mitchell I, Wendon J, Fitt S, Williams R (1995):** Anti-tuberculous therapy and acute liver failure. *Lancet*, **345**: 555-556.
- (58) Lu Y, Zhu LZ, Duan LS (1999):** The anti-TB effects of fluoroquinolone. *Zhonghua Jiehe He Huxi Zazhi*, **22**: 693-695.
- (59) Amarapurkar DN, Prabhudesai PP, Kalro RH, Desai HG (1993):** Antituberculosis drug-induced hepatitis and HBsAg carriers. *Tubercle. Lung. Dis.*, **74**: 215-216.
- (60) El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003):** The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann. Intern. Med.*, **139**: 817-823.
- (61) Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR (2001):** Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. *Clin. Infect. Dis.*, **33**: 1687-1691.
- (62) Fundação Nacional de Saúde (2002):** Tuberculose: Guia de Vigilância Epidemiológica. Brasília: Fundação Nacional de Saúde.